Andrew Levin

Andrew Levin is recorded as CFO at Climb Bio, Inc. (CLYM) since March 10, 2023 and Chairman at Climb Bio, Inc. (CLYM). The newest filing on record that lists Andrew Levin as Chairman at Climb Bio, Inc. (CLYM) is dated April 6, 2023. Climb Bio, Inc. reported in an 8-K filed July 1, 2026 that Andrew Levin resigned as member of the Board, effective June 29, 2026. Climb Bio, Inc. reported in an 8-K filed August 27, 2024 that Andrew Levin was appointed Chairman of the Board, effective August 26, 2024. Climb Bio, Inc. reported in an 8-K filed February 14, 2023 that Andrew Levin was appointed Executive Chairman. Equibles holds 4 filed executive changes naming Andrew Levin; each is listed under recent activity with its source filing. The proxy statement of Climb Bio, Inc. reports total compensation of $124,205 for Andrew Levin in fiscal 2024. Disclosed compensation is on record for 2 fiscal years. Climb Bio, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Climb Bio, Inc. includes Aoife Brennan (CEO, CFO and Board Member), Aoife Brennan, M.B., Ch.B. (CEO and Board Member), Dr. Stephen Thomas (CEO) and 7 others.